Breast Cancer
Prognosis, Treatment, and Prevention
2nd Edition
Published on 11. April 2008
608 pages
978-1-4200-5873-4 (ISBN)
Description
Now in its second edition, this bestselling title has been extensively revised and expanded to include new topics on:obesity and breast cancerinduction of anti-hormone and anti-growth factor resistance in breast cancerclinical implications of testosterone and breast cancerinsulin-like growth factorsdiscussions on the biological, genetic, and molecu
More details
Edition
2nd edition
Language
English
Place of publication
Baton Rouge
United States
Publishing group
Taylor & Francis Inc
Target group
Professional and scholarly
oncologists, endocrinologists, gynecologists, general clinicians, biologists, physiologists, and advanced students.
Edition type
Revised edition
Illustrations
85 s/w Abbildungen, 84 s/w Tabellen, 6 s/w Photographien bzw. Rasterbilder
85 b/w images, 84 tables and 6 halftones
File size
7,07 MB
ISBN-13
978-1-4200-5873-4 (9781420058734)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Book
09/2019
2nd Edition
CRC Press
€49.59
Shipment within 15-20 days
Book
04/2008
2nd Edition
CRC Press
€379.45
Article not available at the moment
Previous edition
E-Book
12/2013
1st Edition
Routledge
€32.99
Available for download
Person
JORGE R. PASQUALINI is Director of the Hormones and Cancer Research Unit at the Institut de Puericulture of Paris. Professor Pasqualini received his Ph.D. in biology from the University of Buenos Aires, Argentina, and a D.Sc. degree in Endocrinology from the University of Paris, France. He has published more than 600 original papers and is the founder and Editor-in-Chief of The Journal of Steroid Biochemistry and Molecular Biology, which is considered to be one of the leading international scientific journals in the field. Professor Pasqualini has worked in varying areas of endocrinology and reproduction, and in recent years found new aspects of the production, control, and biological effect of estrogens, anti-estrogens, and progestins in human breast and endometrial cancers, with potential clinical applications in pre- and postmenopausal patients.
Content
Breast Architecture and the Pathogenesis of Cancer. The Enzymatic Systems in the Formation and Transformation of Estrogens in Normal and Cancerous Human Breast. Control and Potential Clinical Applications. Pregnancy and Breast Cancer. The cellular origins of breast cancer subtypes. The Importance of Estrogen Receptors in Breast Cancer. Progesterone Receptor Isoforms and Human Breast Cancer. Compensatory signaling promoted by anti-hormones and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted treatments. Apoptosis, cell death, and breast cancer. Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer. Aromatase Inhibition In Breast Cancer: Update of Clinical Applications. Testosterone and another androgens in breast cancer: Clinical Implications. Combination of breast cancer prevention with tissue-targeted hormone replacement therapy. Practical progress in the chemoprevention of breast cancer with selective estrogen receptor modulators (SERMs). Oncostatic effect of analogs of LHRH on breast cancer. Vitamin D and Breast Cancer. Insulin-like Growth Factor Signaling in Normal Mammary Gland Development and Breast Cancer Progression. Insulin-like Growth Factor-I and Breast Cancer: Epidemiological and Clinical Data. Proliferation of breast cells by steroid hormones and their metabolites. Lignans and Breast Cancer. Breast Cancer Risk, Soyfood Intake and Isoflavone Exposure: A Review of the In Vitro, Animal, Epidemiologic, and Clinical Literature. Body Size and Breast Cancer. Antiangiogenic therapy of breast cancer: Rationale and clinical results. Cytotoxic Therapy and Other Non-Hormonal Approaches for the Treatment of Metastatic Breast Cancer. Adjuvant and Neoadjuvant Systemic Chemotherapy for Operable and Locally Advanced Breast Cancer. BRCA1, BRCA2, and Hereditary Breast Cancer.
